Waist-to-Height Ratio Emerges as Superior Predictor of Heart Failure Risk Compared to BMI

Waist-to-Height Ratio Emerges as Superior Predictor of Heart Failure Risk Compared to BMI

A major French study published in the European Heart Journal reveals that two out of five patients with heart failure do not see a cardiologist even once a year—a gap linked to significantly higher mortality rates. The study, involving over 655,000 patients and presented at the Heart Failure Congress 2025, found that patients who had at least one cardiologist visit annually were 24% less likely to die in the following year.

Cardiology Follow-Ups Linked to Lower Death Rates in Heart Failure Patients, But Two in Five Miss Out

Cardiology Follow-Ups Linked to Lower Death Rates in Heart Failure Patients, But Two in Five Miss Out

A major French study published in the European Heart Journal reveals that two out of five patients with heart failure do not see a cardiologist even once a year—a gap linked to significantly higher mortality rates. The study, involving over 655,000 patients and presented at the Heart Failure Congress 2025, found that patients who had at least one cardiologist visit annually were 24% less likely to die in the following year.

AI-Driven ECG Tool Shows Promise for Early Heart Failure Detection in Kenya

AI-Driven ECG Tool Shows Promise for Early Heart Failure Detection in Kenya

A recent study presented at Heart Failure 2025, a congress of the European Society of Cardiology (ESC), highlights the promising performance of an artificial intelligence (AI)-enabled electrocardiogram (ECG) algorithm in detecting early signs of heart failure in Kenya. The study specifically focused on identifying left ventricular systolic dysfunction (LVSD), a precursor to heart failure, in a resource-limited setting where access to echocardiography—the gold standard diagnostic tool—is limited.

GMP-Cannabidiol Shows Promising Cardiac Safety in COVID-19 Trial Patients with Cardiovascular Risk

GMP-Cannabidiol Shows Promising Cardiac Safety in COVID-19 Trial Patients with Cardiovascular Risk

A pharmaceutically manufactured cannabidiol (CBD) formulation demonstrated a favorable cardiac safety profile in a prospective, placebo-controlled trial involving patients hospitalized with non-critical COVID-19 and at high risk for cardiovascular events. The findings were presented at the Heart Failure 2025 congress of the European Society of Cardiology (ESC) on 17 May 2025 in Belgrade, Serbia.

Disrupted TGFβ Signaling and Inflammatory Infiltration Underlie Spontaneous Aortic Dissection in Genetically Engineered Mice

Disrupted TGFβ Signaling and Inflammatory Infiltration Underlie Spontaneous Aortic Dissection in Genetically Engineered Mice

The study presents a novel mouse model for spontaneous aortic dissection (AD), developed by introducing a patient-derived FBN1 gene variant (Gly234Asp) using CRISPR/Cas9. This mutation, identified in a family with nonsyndromic AD, leads to early-onset, rapidly progressing aortic dissection in homozygous mutant mice, with a 50% mortality rate by five weeks of age. The mutant mice exhibit multiple intimomedial tears in the ascending aorta, mimicking human pathology. The research identifies early abnormalities in endothelial cells (ECs), such as misalignment with blood flow and upregulation of adhesion molecules (VCAM-1 and ICAM-1), contributing to immune cell recruitment.